1 results match your criteria: "Joan and Sanford I. Weill Cornell Medical Center[Affiliation]"
Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
Mol Pharm
July 2019
Department of Radiology , Joan and Sanford I. Weill Cornell Medical Center, New York , New York 10065 , United States.
A six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a newly identified target in prostate cancer. The use of radio-labeled STEAP1-targeting antibodies with positron emission tomography (PET) may allow for detection of sites of metastatic prostate cancer and may refine patient selection for antigen-directed therapies. This was a prospective study in seven patients with metastatic castration-resistant prostate cancer who had at least one archival biopsy that was STEAP1-positive by immunohistochemistry.
View Article and Find Full Text PDF